Titan Pharmaceuticals Current Ratio 2006-2021 | TTNP

Titan Pharmaceuticals current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Titan Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.01B $0.00B 4.23
2021-03-31 $0.01B $0.00B 3.51
2020-12-31 $0.01B $0.00B 1.74
2020-09-30 $0.01B $0.01B 1.13
2020-06-30 $0.01B $0.01B 1.79
2020-03-31 $0.01B $0.00B 2.75
2019-12-31 $0.01B $0.00B 2.31
2019-09-30 $0.00B $0.00B 1.13
2019-06-30 $0.01B $0.00B 1.27
2019-03-31 $0.01B $0.01B 2.12
2018-12-31 $0.01B $0.00B 3.85
2018-09-30 $0.01B $0.00B 5.23
2018-06-30 $0.00B $0.00B 1.76
2018-03-31 $0.01B $0.00B 1.75
2017-12-31 $0.01B $0.00B 1.86
2017-09-30 $0.01B $0.00B 6.11
2017-06-30 $0.01B $0.00B 4.68
2017-03-31 $0.01B $0.00B 5.42
2016-12-31 $0.02B $0.01B 3.67
2016-09-30 $0.02B $0.01B 3.38
2016-06-30 $0.02B $0.01B 4.02
2016-03-31 $0.01B $0.01B 2.16
2015-12-31 $0.01B $0.01B 2.52
2015-09-30 $0.01B $0.01B 3.02
2015-06-30 $0.02B $0.01B 3.07
2015-03-31 $0.02B $0.01B 3.22
2014-12-31 $0.02B $0.01B 2.94
2014-09-30 $0.01B $0.01B 1.59
2014-06-30 $0.01B $0.01B 1.64
2014-03-31 $0.02B $0.01B 1.59
2013-12-31 $0.02B $0.01B 1.55
2013-09-30 $0.01B $0.01B 1.13
2013-06-30 $0.02B $0.01B 1.13
2013-03-31 $0.02B $0.02B 1.10
2012-12-31 $0.02B $0.02B 1.10
2012-09-30 $0.01B $0.01B 0.86
2012-06-30 $0.01B $0.01B 0.93
2012-03-31 $0.01B $0.01B 1.14
2011-12-31 $0.01B $0.01B 1.95
2011-09-30 $0.01B $0.01B 1.01
2011-06-30 $0.01B $0.01B 1.41
2011-03-31 $0.00B $0.01B 0.36
2010-12-31 $0.01B $0.01B 0.87
2010-09-30 $0.01B $0.01B 1.85
2010-06-30 $0.00B $0.00B 0.84
2010-03-31 $0.01B $0.01B 1.29
2009-12-31 $0.00B $0.00B 2.34
2009-09-30 $0.00B $0.00B 1.17
2009-06-30 $0.00B 0.00
2009-03-31 $0.00B 0.00
2008-12-31 $0.01B $0.00B 2.05
2008-09-30 $0.01B $0.00B 2.97
2008-06-30 $0.02B $0.01B 3.95
2008-03-31 $0.03B $0.00B 5.76
2007-12-31 $0.03B $0.00B 7.16
2007-09-30 $0.01B $0.00B 4.84
2007-06-30 $0.02B $0.00B 5.59
2007-03-31 $0.01B $0.00B 3.38
2006-12-31 $0.01B $0.00B 4.19
2006-09-30 $0.02B $0.00B 4.32
2006-06-30 $0.02B $0.00B 6.92
2006-03-31 $0.02B $0.00B 7.51
2005-12-31 $0.02B $0.00B 5.93
2005-09-30 $0.02B $0.00B 4.46
2005-06-30 $0.03B $0.00B 7.40
2005-03-31 $0.03B $0.00B 7.16
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.019B $0.005B
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71